May. 1, 2011
BeiGene, a Beijing startup that focuses on the development of oncology drugs, announced an initial investment from Merck today. The exact size of the investment was not disclosed. There are 5 cancer drug candidates in BeiGene’s pipeline, two me-better drugs and three with new mechanisms of action.